Phase II study of Bevacizumab + Pemetrexed in elderly patients with advanced non-squamous non-small-cell lung cancer
Latest Information Update: 13 May 2016
Price :
$35 *
At a glance
- Drugs Bevacizumab (Primary) ; Pemetrexed (Primary)
- Indications Non-small cell lung cancer
- Focus Biomarker; Therapeutic Use
- 28 Mar 2016 Status changed from recruiting to discontinued.
- 17 May 2013 New trial record